Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rotigotine + Rivastigmine in Mild to Moderate Alzheimer's Disease
2023-504602-11-00Phase 3Authorised
- Sponsor
- Fondazione Santa Lucia IRCCS
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) comparing Rotigotine + rivastigmine with Placebo + rivastigmine (2 arms). Primary endpoint: Frontal lobe cognitive function (FAB change from baseline to Week 24). Planned start Sep 2023; status: authorised.
02
Drugs
rotigotine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2023-504602-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504602-11-00.